SCHEMBL20239246

SCHEMBL20239246

CNc1nc(CNc2ncc(Cl)cn2)cc(Oc2ccc(NS(C)(=O)=O)cc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.50
GPR39 O43194 3/20 0.41
ADRB2 P07550 1/20 0.40
ADRA2C P18825 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
TSPO P30536 1/20 0.40
HTR7 P34969 1/20 0.40
DRD3 P35462 1/20 0.40
OPRK1 P41145 1/20 0.40
HTR2B P41595 1/20 0.40
GLP1R P43220 1/20 0.40
HTR5A P47898 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
PTK2 Q05397 1/20 0.40
PGR P06401 1/20 0.39
GRIN1 Q05586 4/20 0.38
GRIN2B Q13224 4/20 0.38
KCNH2 Q12809 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239208 0.89 DGAT2 (0.53) DGAT2PTK2PGRGRIN1GRIN2B
SCHEMBL20239259 0.86 DGAT2 (0.49) DGAT2DRD3PTK2PGRGRIN1
SCHEMBL20239245 0.84 DGAT2 (0.69) DGAT2GPR39METRAB9ASMN1; SMN2
SCHEMBL20239200 0.81 DGAT2 (0.76) DGAT2GRIN1GRIN2BKCNH2LTA4H
SCHEMBL20239364 0.81 DGAT2 (0.62) DGAT2PTK2METSMN1; SMN2LMNA
SCHEMBL20239321 0.80 DGAT2 (0.46) DGAT2GPR39PTK2PGRGRIN1
SCHEMBL20239338 0.78 SMN1; SMN2 (0.46) DGAT2GPR39DRD3PTK2PGR
SCHEMBL20239141 0.78 DGAT2 (0.42) DGAT2GPR39DRD3PTK2PGR
SCHEMBL20239203 0.75 DGAT2 (0.59) DGAT2METNPC1RAB9AHPGD
SCHEMBL20239226 0.75 DGAT2 (0.53) DGAT2KCNH2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885GPR39 441/4885ADRB2 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.